World’s First Human Implant of a 3D-Printed Cornea Restores Sight
December 15, 2025
Free CME credits
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
Brand Name :
Advate
Synonyms :
Octocog alfa, factor VIII
Class :
Hemostatics
Brand Name :
Advate
Synonyms :
Octocog alfa, factor VIII
Class :
Hemostatics
Dosage Forms & Strengths
Powder for injection
250 IU
Minor bleeding: 10-20 IU/kg intravenously one to two times a day for 1 to 3 days
Moderate bleeding: 15-30 IU/kg intravenously one to two times a day for almost three days
Major bleeding: 30-50 IU/kg intravenously one to three times until bleeding seizes
Minor surgery: 30-50 IU/kg intravenously as single about an hour before the start of the procedure
Note: repeat after half a day or one day as required
Major surgery: 40-60 IU/kg intravenously before the operation. Repeat 2 to 3 times based on the nature of wound healing
Prophylaxis: 20-40 IU/kg three to four times per week. Doses are to be administered as infusions slowly at ≤ 5 minutes and to a maximum rate of 10ml/minute
Dosage Forms & Strengths
Powder for injection
250 IU
For children under six years:
Minor bleeding: 10-20 IU/kg intravenously three to four times a day for 1 to 3 days
For children more than six years old:
Minor bleeding: 10-20 IU/kg intravenously one to two times a day for 1 to 3 days
For children under six years:
Moderate bleeding: 15-30 IU/kg intravenously three to four times a day for almost three days
For children more than six years old:
Moderate bleeding: 15-30 IU/kg intravenously one to two times a day for almost three days
For children under six years:
Major bleeding: 30-50 IU/kg intravenously for one to two times until bleeding seizes
For children more than six years old:
Major bleeding: 30-50 IU/kg intravenously one to three times until bleeding seizes
For children under the age of 6 years
Major surgery: 40-60 IU/kg intravenously before the operation. Repeat one to four times based on the nature of wound healing
For children more than six years
Major surgery: 40-60 IU/kg intravenously before the operation. Repeat 2 to 3 times based on the nature of wound healing
Prophylaxis:
For children under the age of 6 years:
20- 50 IU/kg intravenously three to four times a day
For children more than six years old:
20-40 IU/kg three to four times per week. Doses are to be administered as infusions slowly at ≤ 5 minutes and to a maximum rate of 10ml/minute
Refer to adult dosing.
Actions and spectrum:
Octocog alfa acts like human coagulation factor VIII. It sets off a chain, activating factor X. This triggers fibrinogen converting into fibrin, enabling blood clotting.
Frequency not defined
Anaphylaxis
Dizziness
Somnolence
Malaise
Asthenia
Depersonalization
Bacteraemia
Cather-site thrombosis
Chest tightness
Diarrhea
Unpleasant taste
Rhinitis
Nasal congestion
Epistaxis
Ear infection
Arthralgia
Pruritis
Flu-like symptoms
Reactions at the site of injection
Swelling of joints
Black Box Warning
No special warnings are available
Contraindication/Caution:
Contraindication:
Hypersensitivity
Precautions:
Pregnancy
Lactation
Monitor closely
Signs of bleeding
Hematocrit
Blood pressure
Heart rate
Pregnancy consideration:
Data is not available
Lactation:
Data about the excretion of octocog alfa into human milk is not known.
Pregnancy category:
Category A: Studies that were well-controlled and met expectations revealed no risk to the fetus in either the first or second trimester.
<b>Category B: There was a lack of studies on pregnant women and no evidence of risk to the fetus in animal experiments.
Category C: there was evidence of risk of adverse effects in animal reproduction studies, and no adequate evidence in human studies must take care of potential risks in pregnant women.
Category D: adequate data with sufficient evidence of human fetal risk from various platforms, but despite the potential risk, and used only in emergency cases for potential benefits.
Category X: Drugs listed in this category outweigh the risks over benefits. Hence, these categories of drugs need to be avoided by pregnant women.
Category N: There is no data available for the drug under this category
Pharmacology:
Octocog alfa functions as an antihemophilic agent. It represents second-generation recombinant factor VIII replacement therapy for hemophilia treatment.
Pharmacodynamics:
Limited data available
Pharmacokinetics:
Absorption
After intravenous administration, peak plasma levels occur within 10-15 minutes.
Distribution
In circulation, 14% remains extravascular. Mainly binding von Willebrand factor, its half-life is around 12 hours.
Administration:
Give octocog alfa by IV. But, first ensure the reconstituted liquid looks see-through, colorless, and free from particles.
Patient information leaflet
Generic Name: octocog alfa
Why do we use octocog alfa?
Octocog alfa replaces low factor VIII. It treats hemophilia, a bleeding disorder. It works by fixing clotting problems. Octocog alfa is a newer factor VIII therapy. It provides vital treatment for factor VIII deficiency.
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
On course completion, you will receive a full-sized presentation quality digital certificate.
A dynamic medical simulation platform designed to train healthcare professionals and students to effectively run code situations through an immersive hands-on experience in a live, interactive 3D environment.
When you have your licenses, certificates and CMEs in one place, it's easier to track your career growth. You can easily share these with hospitals as well, using your medtigo app.
